GleamWall
中文EN

BKHA Black Hawk Acquisition Corp

Biological Products, (No Diagnostic Substances) · Nasdaq · SEC CIK 2000775 · Fiscal year ends 11/30

Financial factors as of 2026-08-31 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY—
TTM net income YoY-37.7%
TTM EPS YoY—
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—

Returns

ROE—
ROA5.3%
ROIC (approx.)—
Asset turnover—

Leverage & solvency

Liabilities / assets18.2%
Debt / equity—
Current ratio0.02x
Interest coverage—

Cash quality & payout

Operating cash flow / net income-0.43x
Accruals ratio7.5%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item 2026Q32026-08-312026Q22026-05-312026Q12026-02-282025Q4*2025-11-302025Q32025-08-312025Q22025-05-312025Q12025-02-282024Q4*2024-11-30
Income statement
Revenue————————
SG&A expense$108,210$79,215$24,189$187,878$311,265$217,598$78,769$71,268
Operating income-$138,210-$109,215-$54,189-$217,878-$341,265-$247,598-$108,769-$101,268
Interest expense$33,226$24,381$19,449—————
Net income$1.07M$88,929$139,805-$3,765$154,401$520,542$658,379$751,701
EPS (diluted)————————
Banking
Net interest income$230,184$222,525$213,442$230,578$494,519$767,623$765,911$850,603
Deposits$690,000$690,000$690,000$690,000$690,000$690,000$690,000$690,000
Balance sheet
Cash & equivalents$0$0$0$0$15,000$72,914$101,528$264,842
Current assets$41,367$63,130$181,352$50,790$44,530$139,523$205,262$314,071
Intangibles$5.00M$5.00M$5.00M$5.00M$5.00M———
Total assets$26.03M$25.38M$24.82M$23.88M$23.34M$73.50M$72.80M$72.14M
Current liabilities$2.34M$2.75M$2.29M$1.48M$946,168$251,043$69,701$70,978
Total liabilities$4.75M$5.17M$4.70M$3.90M$3.36M$2.67M$2.48M$2.49M
Shareholders' equity-$4.71M-$5.10M-$4.52M-$3.85M-$3.32M-$2.53M-$2.28M-$2.17M
Cash flow statement
Operating cash flow-$113,451-$236,637-$109,502-$100,479-$107,914-$278,614-$163,314-$59,004
Investing cash flow-$450,000-$450,000-$600,000-$300,000———$0
Financing cash flow$563,920$519,813$848,388$425,000-$50.51M——$0

Free plan shows the latest 8 periods; Pro shows all 11 🔒

· This company does not report gross profit in XBRL.

· This company reports EPS only by share class (e.g. class A/B), so it is shown as —.

· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.